Neoplasmata
Conditions
Brief summary
The investigators aim to collect tumor DNA out of blood of cancer patients. If this is successful this could lead to the development of a cancer test in blood in the future, which is less invasive than current diagnostic methods.
Interventions
GENETICIsolation of tumor DNA
Sponsors
Maastricht University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with newly diagnosed local or metastatic breast cancer, colorectal cancer, non-small cell lung cancer and anaplastic glioblastoma, before start of radiation therapy, chemoradiation or chemotherapy. 2. Patients age \> 18 years, willing and able to comply with the protocol as judged by the investigator with a signed informed consent
Exclusion criteria
1. Patients with a history of malignant disease other than the disease under study, with an exception for adequately treated squamous cell carcinoma of the skin, basal cell carcinoma of the skin and in situ cervix carcinoma. 2. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ctDNA | One year | Demonstrate the presence or absence of ctDNA in patients plasma. Examine if there us a sufficient concentration of ctDNA in the plasma to reliably diagnose cancer and determine the CNV |
Countries
Netherlands
Contacts
Primary ContactMerryn M. Macville, Dr.
Backup ContactJob J. Verdonschot, Drs.
Outcome results
None listed